Results 21 to 30 of about 181,344 (173)

Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells [PDF]

, 2012
For a long time necrosis was thought to be an uncontrolled process but evidences recently have revealed that necrosis can also occur in a regulated manner.
Barna, Gabor, Bauer, Pal I., Dunai, Zsuzsanna A., Imre, Gergely, Korcsmaros, Tamas, Mihalik, Rudolf, Petak, Istvan   +6 more
core   +3 more sources

Design, Synthesis, Evaluation, and Structural Studies of C₂-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction

Journal of Medicinal Chemistry, 2019
A series of C2-symmetric inhibitors was designed and evaluated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (PPI) in a homogenous time-resolved fluorescence (HTRF) assay and PD-1 signaling in cell-based coculture assays.
Subhadwip Basu, Jeffrey Yang, Bin Xu, Katarzyna Magiera-Mularz, Lukasz Skalniak, Bogdan Musielak, Vladyslav Kholodovych, Tad A. Holak, Longqin Hu   +8 more
openaire   +3 more sources

Porphyromonas gingivalis Cell Wall Components Induce Programmed Death Ligand 1 (PD-L1) Expression on Human Oral Carcinoma Cells by a Receptor-Interacting Protein Kinase 2 (RIP2)-Dependent Mechanism

Infection and Immunity, 2020
Programmed death-ligand 1 (PD-L1/B7-H1) serves as a cosignaling molecule in cell-mediated immune responses and contributes to chronicity of inflammation and the escape of tumor cells from immunosurveillance. Here, we investigated the molecular mechanisms leading to PD-L1 upregulation in human oral carcinoma cells and in primary human ...
S, Groeger, F, Denter, G, Lochnit, M L, Schmitz, J, Meyle   +4 more
openaire   +3 more sources

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1

Chinese Medical Journal, 2020
. Historically, breast cancer has been regarded as an immunogenic “cold” tumor. However, the discovery of immune checkpoint inhibitors has made immunotherapy becoming an emerging new treatment modality for breast cancer.
Jing Zhao, Jian Huang, Qiang Shi
doaj   +1 more source

Immune checkpoint inhibitor‐induced asthma and chronic obstructive pulmonary disease overlap in patient with adenocarcinoma

Respirology Case Reports, 2023
A 67‐year‐old current smoker Japanese man, with no history of asthma, was diagnosed with lung adenocarcinoma. He received first‐line chemotherapy with carboplatin, pemetrexed, ipilimumab, and nivolumab in July 20XX‐1, and subsequently a maintenance ...
Yuki Hayakawa, Takako Kawaguchi, Kei Yamasaki, Miyu Endo, Masaya Komatsu, Yutaka Ishiguro, Yuichi Murata, Kazuhiro Yatera   +7 more
doaj   +1 more source

Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy

Pharmaceutics, 2022
Programmed cell death protein 1/Programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors are the most promising treatments for malignant tumors currently, but the low response rate limits their further clinical utilization.
De-Xi Zhou, Xiao-He Wang, Xuan Xu, Wen-Jie Chen, Jing Wei, Ting-Tao Chen, Hong Wei   +6 more
doaj   +1 more source

Human T cell glycosylation and implications on immune therapy for cancer [PDF]

, 2020
Glycosylation is an important post-translational modification, giving rise to a diverse and abundant repertoire of glycans on the cell surface, collectively known as the glycome.
Callewaert, Nico, De Bousser, Elien, Festjens, Nele, Meuris, Leander   +3 more
core   +1 more source

A Dramatic Response to Toripalimab With Chemotherapy and Antiangiogenic Agent Followed by Surgery in a Stage IIIB Lung Adenocarcinoma Patient With an Uncommon EGFR Mutation: A Case Report

Frontiers in Oncology, 2022
Lung cancer patients with high programmed cell death-ligand 1 (PD-L1) expression in tumor cells and epidermal growth factor receptor (EGFR) mutations are rare, but there is no clinical standard for which treatment such patients should receive.
Pengda Zhai, Xueliang Niu, Kai Zheng
doaj   +1 more source

Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model [PDF]

Investigative and Clinical Urology, 2023
Purpose: Programmed cell death protein 1 (PD-1) and ligand programmed death ligand 1 (PD-L1) are important immune-suppressive regulators in the tumor microenvironment.
Soyeon Lim, Jun-Hee Park, Hyun Chang
doaj   +1 more source

Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. [PDF]

, 2016
BackgroundMalignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade.
Bernthal, Nicholas, Chmielowski, Bartosz, Crompton, Joseph G, Dry, Sarah, Eilber, Fritz C, Federman, Noah, Jensen, Sarah, Li, Yunfeng, Nelson, Scott, Shurell, Elizabeth, Singh, Arun S, Tumeh, Paul   +11 more
core   +2 more sources